SELECTIVE TREATMENT OF ENDOTHELIAL SOMATOSTATIN RECEPTORS

摘要

The invention provides for the use of a SSTR1 or SSTR4 selective agonist to treat human endothelial cells and to formulate a medicament for human use, where the medicament may be for use to treat an endothelial-cell-mediated proliferative disease. The use of SSTR1 or SSTR4 selective agonists for treating endothelial-cell-mediated proliferative diseases may include, for example, treatment of intimal hyperplasia or an angiogenic disease. In vario us embodiments, the angiogenic disease may for example be macular degeneration, or a solid tumor. The SSTR1 or SSTR4 selective agonists may include the SSTR 1 '499 agonist (des-AA1,2,5[DTrp8,IAamp9]SS). In methods of treatment, therapeutically effective amounts of the SSTR1 or SSTR4 selective agonists m ay be administered to a patient.